NASDAQ:GNLX Genelux (GNLX) Stock Price, News & Analysis $2.96 -0.04 (-1.33%) (As of 11/12/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Genelux Stock (NASDAQ:GNLX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Genelux alerts:Sign Up Key Stats Today's Range$2.87▼$2.9950-Day Range$1.98▼$3.3352-Week Range$1.60▼$16.60Volume84,026 shsAverage Volume179,946 shsMarket Capitalization$102.22 millionP/E RatioN/ADividend YieldN/APrice Target$18.75Consensus RatingBuy Company OverviewGenelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.Read More… New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Genelux Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks35th Percentile Overall ScoreGNLX MarketRank™: Genelux scored higher than 35% of companies evaluated by MarketBeat, and ranked 691st out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingGenelux has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageGenelux has only been the subject of 4 research reports in the past 90 days.Read more about Genelux's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Genelux are expected to decrease in the coming year, from ($0.89) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genelux is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genelux is -3.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenelux has a P/B Ratio of 4.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genelux's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.15% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Genelux has recently increased by 37.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenelux does not currently pay a dividend.Dividend GrowthGenelux does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.15% of the float of Genelux has been sold short.Short Interest Ratio / Days to CoverGenelux has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Genelux has recently increased by 37.50%, indicating that investor sentiment is decreasing significantly. News and Social Media2.6 / 5News Sentiment0.62 News SentimentGenelux has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Genelux this week, compared to 1 article on an average week.Search Interest5 people have searched for GNLX on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Genelux to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Genelux insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $736,831.00 in company stock.Percentage Held by InsidersOnly 9.30% of the stock of Genelux is held by insiders.Percentage Held by InstitutionsOnly 37.33% of the stock of Genelux is held by institutions.Read more about Genelux's insider trading history. Receive GNLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genelux and its competitors with MarketBeat's FREE daily newsletter. Email Address GNLX Stock News HeadlinesGenelux Corp. Releases New Corporate PresentationNovember 9 at 2:44 PM | markets.businessinsider.comGenelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation ConferenceNovember 6, 2024 | globenewswire.com“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…November 12, 2024 | Colonial Metals (Ad)Genelux (NASDAQ:GNLX) Now Covered by Analysts at GuggenheimNovember 2, 2024 | americanbankingnews.comIndividual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as wellOctober 31, 2024 | finance.yahoo.comGenelux initiated with a Buy at GuggenheimOctober 30, 2024 | markets.businessinsider.comGuggenheim Initiates Coverage of Genelux (GNLX) with Buy RecommendationOctober 30, 2024 | msn.comHighbridge Capital Management LLC Acquires Significant Stake in Genelux CorpOctober 25, 2024 | finance.yahoo.comSee More Headlines GNLX Stock Analysis - Frequently Asked Questions How have GNLX shares performed this year? Genelux's stock was trading at $14.01 on January 1st, 2024. Since then, GNLX stock has decreased by 78.9% and is now trading at $2.96. View the best growth stocks for 2024 here. How were Genelux's earnings last quarter? Genelux Co. (NASDAQ:GNLX) announced its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03. When did Genelux IPO? Genelux (GNLX) raised $16 million in an initial public offering (IPO) on Thursday, January 26th 2023. The company issued 2,500,000 shares at $6.00-$7.00 per share. The Benchmark Company and Brookline Capital Markets acted as the underwriters for the IPO. Who are Genelux's major shareholders? Top institutional shareholders of Genelux include LifeSteps Financial Inc. (0.23%), Exchange Traded Concepts LLC (0.19%) and Miracle Mile Advisors LLC (0.12%). Insiders that own company stock include Aladar Szalay, John Thomas, Sean Ryder, Caroline Jewett, Thomas Zindrick, Yong Yu, John W Smither, Joseph Cappello, Doug Samuelson and Qian Zhang. View institutional ownership trends. How do I buy shares of Genelux? Shares of GNLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Genelux own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genelux investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), Netflix (NFLX) and Palo Alto Networks (PANW). Company Calendar Last Earnings8/14/2024Today11/12/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GNLX CUSIPN/A CIK1231457 Webwww.genelux.com Phone805-267-9889FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$18.75 High Stock Price Target$32.00 Low Stock Price Target$8.00 Potential Upside/Downside+533.4%Consensus RatingBuy Rating Score (0-4)3.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,300,000.00 Net MarginsN/A Pretax Margin-331,724.97% Return on Equity-110.28% Return on Assets-80.53% Debt Debt-to-Equity RatioN/A Current Ratio6.01 Quick Ratio6.01 Sales & Book Value Annual Sales$8,000.00 Price / Sales12,777.95 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book4.05Miscellaneous Outstanding Shares34,535,000Free Float31,323,000Market Cap$102.22 million OptionableNot Optionable Beta-1.85 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:GNLX) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCritical warning from the mountains of CarolinaNvidia CEO Jensen Huang says Big Tech will spend over $1 trillion on data centers. And that still might not...Weiss Ratings | SponsoredCrypto’s FINAL Wealth MomentBitcoin’s final bull market is here. If you missed out on the gains in 2017, or 2021… 2025 stands to be jus...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.